IP Library Granted Patent US 12,428,448
Granted Patent B1
US 12,428,448 · App. 17/590,166 · Granted Sep 30, 2025

Alphavirus immunogens and methods of use

Inventors: William M. Fischer (Los Alamos, NM); Peter T. Hraber (Los Alamos, NM)
Assignee: Triad National Security, LLC
C07K14/005A61K39/12A61K2039/70C12N2770/36122C12N2770/36134
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,428,448
App. No.
17/590,166
Granted
Sep 30, 2025
Kind
B1
Abstract

Synthetic immunogenic polypeptides based on a curated set of natural alphavirus structural protein sequences are described. The polypeptides were computationally designed to provide optimal coverage of potential immunogenic epitopes of wild-type alphaviruses, including isolates of Venezuelan equine encephalitis virus, Western equine encephalitis virus, Eastern equine encephalitis virus and Chikungunya virus. Sets of immunogenic polypeptides, as well as nucleic acid molecules and vectors encoding the immunogenic polypeptides are also described. The disclosed compositions can be used to elicit an immune response against alphaviruses in a subject.

Claims (46)

1. A synthetic immunogenic polypeptide comprising:

an amino acid sequence at least 99% identical to any one of SEQ ID NOs: 2, 4-6, 8, 11, 15, 17, 19,21 and 24; or

the amino acid sequence set forth as any one of SEQ ID NOs: 1, 3, 9, 13, 18 and 264-26.

2. The synthetic immunogenic polypeptide of claim 1 , wherein the amino acid sequence of the polypeptide comprises or consists of any one of SEQ ID NOs: 1-6, 8, 9, 11, 13, 15, 17-19, 21, 24 and 26.

3. A set of synthetic immunogenic polypeptides comprising two or more polypeptides selected from polypeptides comprising:

an amino acid sequence having at least 99% identity to the amino acid sequence set forth as any one of SEQ ID NOs: 2, 4-6, 8, 11, 15, 17, 19, 21 and 24; or

the amino acid sequence set forth as any one of SEQ ID NOs: 1, 3, 9, 13, 18 and 26.

4. The set of synthetic immunogenic polypeptides of claim 3 , further comprising one or more additional polypeptides selected from polypeptides comprising the amino acid sequence set forth as any one of SEQ ID NOs: 7, 10, 12, 14, 16, 20, 22, 23 and 25.

5. The set of synthetic immunogenic polypeptides of claim 3 , wherein the two or more polypeptides are selected from polypeptides having an amino acid sequence consisting of the amino acid sequences set forth as any one of SEQ ID NOs: 1-6, 8, 9, 11, 13, 15, 17-19, 21, 24 and 26.

6. A set of synthetic immunogenic polypeptides, comprising:

three synthetic polypeptides having amino acid sequences comprising or consisting of the amino acid sequences of SEQ ID NO: 6, SEQ ID NO: 9 and SEQ ID NO: 12;

three synthetic polypeptides having amino acid sequences comprising or consisting of the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 7 and SEQ ID NO: 10;

six synthetic polypeptides having amino acid sequences comprising or consisting of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10 and SEQ ID NO: 13;

five synthetic polypeptides having amino acid sequences comprising or consisting of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10;

six synthetic polypeptides having amino acid sequences comprising or consisting of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11 and SEQ ID NO: 12;

six synthetic polypeptides having amino acid sequences comprising or consisting of the amino acid sequences of SEQ ID NO: 4, SEQ ID NO; 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 10 and SEQ ID NO: 13;

five synthetic polypeptides having amino acid sequences comprising or consisting of the amino acid sequences of SEQ ID NO: 4, SEQ ID NO; 5, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 10;

seven synthetic polypeptides having amino acid sequences comprising or consisting of the amino acid sequences of SEQ ID NO: 4, SEQ ID NO; 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 11, SEQ ID NO: 12 and SEQ ID NO: 13;

six synthetic polypeptides having amino acid sequences comprising or consisting of the amino acid sequences of SEQ ID NO: 4, SEQ ID NO; 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 11 and SEQ ID NO: 12; or

seven synthetic polypeptides having amino acid sequences comprising or consisting of the amino acid sequences of SEQ ID NO: 4, SEQ ID NO; 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11 and SEQ ID NO: 12.

7. A nucleic acid molecule or vector encoding the synthetic immunogenic polypeptide of claim 1 .

8. A recombinant host cell comprising the nucleic acid molecule or vector of claim 7 .

9. A nucleic acid molecule or vector encoding the set of synthetic immunogenic polypeptides of claim 6 .

10. A recombinant host cell comprising the nucleic acid molecule or vector of claim 9 .

11. A set of isolated nucleic acid molecules comprising two or more nucleic acid molecules, wherein each nucleic acid molecule encodes an immunogenic polypeptide selected from polypeptides comprising:

an amino acid sequence having at least 99% identity to the amino acid sequence set forth as any one of SEQ ID NOs: 2, 4-6, 8, 11, 15, 17, 19, 21 and 24; or

the amino acid sequence set forth as any one of SEQ ID NOs: 1, 3, 9, 13, 18 and 26.

12. The set of isolated nucleic acid molecules of claim 11 , further comprising one or more additional nucleic acid molecules, wherein the one or more additional nucleic acid molecules encodes an immunogenic polypeptide selected from polypeptides comprising the amino acid sequence set forth as any one of SEQ ID NOs: 7, 10, 12, 14, 16, 20, 22, 23 and 25.

13. The set of isolated nucleic acid molecules of claim 11 , wherein the two or more nucleic acid molecules each encode an immunogenic polypeptide selected from polypeptides having an amino acid sequence consisting of the amino acid sequences set forth as any one of SEQ ID NOs: 1-6, 8, 9, 11, 13, 15, 17-19, 21, 24 and 26.

14. A set of isolated nucleic acid molecules, comprising:

three nucleic acid molecules encoding polypeptides having amino acid sequences comprising or consisting of the amino acid sequences of SEQ ID NO: 6, SEQ ID NO: 9 and SEQ ID NO: 12;

three nucleic acid molecules encoding polypeptides having amino acid sequences comprising or consisting of the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 7 and SEQ ID NO: 10;

six nucleic acid molecules encoding polypeptides having amino acid sequences comprising or consisting of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10 and SEQ ID NO: 13;

five nucleic acid molecules encoding polypeptides having amino acid sequences comprising or consisting of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10;

six nucleic acid molecules encoding polypeptides having amino acid sequences comprising or consisting of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11 and SEQ ID NO: 12;

six nucleic acid molecules encoding polypeptides having amino acid sequences comprising or consisting of the amino acid sequences of SEQ ID NO: 4, SEQ ID NO; 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 10 and SEQ ID NO: 13;

five nucleic acid molecules encoding polypeptides having amino acid sequences comprising or consisting of the amino acid sequences of SEQ ID NO: 4, SEQ ID NO; 5, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 10;

seven nucleic acid molecules encoding polypeptides having amino acid sequences comprising or consisting of the amino acid sequences of SEQ ID NO: 4, SEQ ID NO; 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 11, SEQ ID NO: 12 and SEQ ID NO: 13;

six nucleic acid molecules encoding polypeptides having amino acid sequences comprising or consisting of the amino acid sequences of SEQ ID NO: 4, SEQ ID NO; 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 11 and SEQ ID NO: 12; or

seven nucleic acid molecules encoding polypeptides having amino acid sequences comprising or consisting of the amino acid sequences of SEQ ID NO: 4, SEQ ID NO; 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11 and SEQ ID NO: 12.

15. A vector or a plurality of vectors comprising the set of isolated nucleic acid molecules of claim 14 .

16. A recombinant host cell comprising the vector or plurality of vectors of claim 15 .

17. A composition comprising the set of synthetic immunogenic polypeptides of claim 6 .

18. The composition of claim 17 , further comprising a pharmaceutically acceptable carrier and/or an adjuvant.

19. A method of eliciting an immune response against one or more alphaviruses in a subject, comprising administering to the subject an effective amount of the set of synthetic immunogenic polypeptides of claim 6 .

20. The method of claim 19 , wherein the one or more alphaviruses comprises Venezuelan equine encephalitis virus, Western equine encephalitis virus, Eastern equine encephalitis virus, Chikungunya virus, or any combination thereof.

Assignments (2)
CONFIRMATORY LICENSE Recorded Aug 30, 2022
From: TRIAD NATIONAL SECURITY, LLC
To: U.S. DEPARTMENT OF ENERGY
Reel/Frame 060934/0980 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2022
From: FISCHER, WILLIAM M.; HRABER, PETER T.
To: TRIAD NATIONAL SECURITY, LLC
Reel/Frame 058851/0629 →
Continuity (1)
Provisional Application 63144551 · Feb 2, 2021
References Cited (19)
US 9555090B2 · Dupuy et al. · 2017 [cited by applicant]
US 20200345838A1 · Clark · 2020 [cited by examiner]
UniProt ID M1KF82_EEVV, V1 2013. https://rest.uniprot.org/unisave/M1KF82?format=txt&versions=1. Accessed Apr. 25, 2025. (Year: 2013). [cited by examiner]
UniProt ID M1KF47_EEVV, V1 2013. https://rest.uniprot.org/unisave/M1KF47?format=txt&versions=1. Accessed Apr. 25, 2025. (Year: 2013). [cited by examiner]
UniProt ID C7T0L5_EEVV, V1 2009. https://rest.uniprot.org/unisave/C7T0L5?format=txt&versions=1. Accessed Apr. 25, 2025. (Year: 2009). [cited by examiner]
UniProt ID M1KF13_EEVV, V1 2013. https://rest.uniprot.org/unisave/M1KF13?format=txt&versions=1. Accessed Apr. 25, 2025. . (Year: 2013). [cited by examiner]
UniProt ID A0A068BBW7_WEEV, V1 2014. https://rest.uniprot.org/unisave/A0A068BBW7?format=txt&versions=1. Accessed Apr. 25, 2025. (Year: 2014). [cited by examiner]
UniProt ID C7DYC0_9VIRU, V1 2009. https://rest.uniprot.org/unisave/C7DYC0?format=txt&versions=1. Accessed Apr. 25, 2025. (Year: 2009). [cited by examiner]
UniProt ID A1YZ44_EEEV, V1 2007. https://rest.uniprot.org/unisave/A1YZ44?format=txt&versions=1. Accessed Apr. 25, 2025. (Year: 2007). [cited by examiner]
UniProt ID D2X872_EEEV, V1 2010. https://rest.uniprot.org/unisave/D2X872?format=txt&versions=1. Accessed Apr. 25, 2025. (Year: 2010). [cited by examiner]
UniProt ID Q1H8W5_CHIKV, V1 2006. https://rest.uniprot.org/unisave/Q1H8W5?format=txt&versions=1. Accessed Apr. 25, 2025. (Year: 2006). [cited by examiner]
UniProt ID M1JR58_EEVV, V1 2013. https://rest.uniprot.org/unisave/M1JR58?format=txt&versions=1. Accessed Apr. 25, 2025. (Year: 2013). [cited by examiner]
UniProt ID M1KFF6_EEVV, V1 2013. https://rest.uniprot.org/unisave/M1KFF6?format=txt&versions=1. Accessed Apr. 25, 2025. (Year: 2013). [cited by examiner]
UniProt ID C7T0M0_EEVV, V1 2009. https://rest.uniprot.org/unisave/C7T0M0?format=txt&versions=1. Accessed Apr. 25, 2025. (Year: 2009). [cited by examiner]
UniProt ID W8R6F6_EEEV, V1 2014. https://rest.uniprot.org/unisave/W8R6F6?format=txt&versions=1. Accessed Apr. 25, 2025. (Year: 2014). [cited by examiner]
UniProt ID D2KBQ2_CHIKV, V1 2010. https://rest.uniprot.org/unisave/D2KBQ2?format=txt&versions=1. Accessed Apr. 25, 2025. (Year: 2010). [cited by examiner]
U.S. Appl. No. 17/590,166_alignments. Alignments of claimed SEQ ID Nos. to various deposited UniProt sequences. (Year: 2025). [cited by examiner]
Theiler et al., “Graph-Based Optimization of Epitope Coverage for Vaccine Antigen Design” [cited by applicant]
Wolfe et al., “Perspective Piece: Current Strategic Thinking for the Development of a Trivalent Alphavirus Vaccine for Human Use,” [cited by applicant]